FDA Grants Priority Review to Roche's Tecentriq for Advanced Colon Cancer

Roche's supplemental Biologics License Application for Tecentriq, in combination with chemotherapy for stage III colon cancer, has received Priority Review status from the FDA. This designation accelerates the review process, with a decision anticipated by October 2026. The application is supported by Phase III study data showing a significant reduction in recurrence or death risk when Tecentriq is added to standard chemotherapy.